Research progress on posttransplant lymphoproliferative disease after lung transplantation
10.3969/j.issn.1674-7445.2021.05.016
- VernacularTitle:肺移植术后淋巴组织增生性疾病的研究进展
- Author:
Le BAN
1
;
Ji ZHANG
;
Min ZHOU
;
Hongmei WANG
;
Wenjun MAO
;
Jingyu CHEN
Author Information
1. Department of Lung Transplantation, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi 214000, China
- Publication Type:Research Article
- Keywords:
Lung transplantation;
Chronic lung allograft dysfunction (CLAD);
Posttransplant lymphoproliferative disease (PTLD);
Epstein-Barr virus (EBV);
Immunosuppression;
Rituximab;
Graft-versus-host disease (GVHD);
Bronchiolitis obliterans syndrome
- From:
Organ Transplantation
2021;12(5):607-
- CountryChina
- Language:Chinese
-
Abstract:
Posttransplant lymphoproliferative disease (PTLD) is a fatal complication after lung transplantation, which is intimately associated with age, immunosuppression level and Epstein-Barr virus (EBV) infection, etc. Reducing immunosuppression level, rituximab therapy and T cell immunotherapy are common treatments for PTLD. With the rapid development of lung transplantation in China, PTLD after lung transplantation has attracted widespread attention. This article reviews the risk factors, pathological types, clinical manifestations, diagnosis, treatment, prognosis and prevention of PTLD after lung transplantation, aiming to provide reference for early monitoring and management of the incidence and progression of PTLD.
